BIOMARIN PHARMACEUTICAL INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 105 DIGITAL DRIVE, NOVATO, CA, 94949
Mailing Address 105 DIGITAL DRIVE, NOVATO, CA, 94949
Phone 4155066700
Fiscal Year End 1231
EIN 680397820
Financial Overview
FY2024
$1.89B
Total Liabilities
$2.25
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 5 Annual insider ownership changes | February 13, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 13, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 13, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 13, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 13, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | January 29, 2026 | View on SEC |
| 8-K Current report of material events | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
Material Events
8-K Strategy Change December 22, 2025
High Impact
- BioMarin Pharmaceutical Inc. has stopped the development of BMN 349, an oral drug for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease.
- This decision represents a significant setback, as it means a substantial investment of time, money, and resources will not result in a marketable product.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.